GlucoTrack, Inc.
GCTK Healthcare Medical Instruments & Supplies
In the quarter to June 2026, EPS grew 92.1%, free cash flow grew 3.42% and total debt rose 777.8%, each against the same quarter a year earlier.
Follow GCTK
GlucoTrack, Inc. (GCTK) Beneish M-score
GlucoTrack, Inc.'s Beneish M-score for fiscal 2019 is 2.40; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2019 | 2.40 | 17.37 |
| FY2018 | −14.97 | 0.06 |
| FY2017 | −15.03 | (15.39) |
| FY2016 | 0.36 | 5.03 |
| FY2015 | −4.67 | — |
How fiscal 2019’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 0.64 | — | 0.59 | |
| Gross margin index | 1.00 | — | 0.53 | |
| Asset quality index | 0.68 | — | 0.28 | |
| Sales growth index | 4.78 | — | 4.27 | |
| Depreciation index | 1.02 | — | 0.12 | |
| SG&A index | 0.12 | — | −0.02 | |
| Total accruals to total assets | 0.35 | — | 1.64 | |
| Leverage index | 0.46 | — | −0.15 | |
| Beneish M-score | Flagged by the model | 2.40 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| RVP Retractable Technologies, Inc. compare | −15.4× |
| NXGL NexGel, Inc. compare | −3.4× |
| BNGO Bionano Genomics, Inc. compare | −3.4× |
| LUCY Innovative Eyewear, Inc. compare | −2.4× |
| FEMY Femasys Inc. compare | −2.2× |
| MHUAF Meihua International Medical Technologies Co., Ltd. compare | −1.8× |
| GCTK GlucoTrack, Inc. | 2.4× |
| RGNT Regentis Biomaterials Ltd. compare | — |
| CUPR Cuprina Holdings (Cayman) Limited compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI